| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9169307 | APELLIS PHARMS | Potent compstatin analogs |
Nov, 2027
(3 years from now) | |
| US7989589 | APELLIS PHARMS | Compstatin analogs with improved activity |
Dec, 2027
(3 years from now) | |
| US7888323 | APELLIS PHARMS | Potent compstatin analogs |
Dec, 2027
(3 years from now) | |
| US11661441 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Jan, 2033
(8 years from now) | |
| US10125171 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
Aug, 2033
(9 years from now) | |
| US10875893 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US10035822 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| US11292815 | APELLIS PHARMS | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
Nov, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11040107 | APELLIS PHARMS | Dosing regimens and related compositions and methods |
Apr, 2038
(13 years from now) | |
Empaveli is owned by Apellis Pharms.
Empaveli contains Pegcetacoplan.
Empaveli has a total of 9 drug patents out of which 0 drug patents have expired.
Empaveli was authorised for market use on 14 May, 2021.
Empaveli is available in solution;subcutaneous dosage forms.
Empaveli can be used as treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan so as to reduce the sensitivity of cells to complement-dependent damage, treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of pegcetacoplan, treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly, treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of complement inhibitor pegcetacoplan.
Drug patent challenges can be filed against Empaveli from 14 May, 2025.
The generics of Empaveli are possible to be released after 09 April, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
| Orphan Drug Exclusivity(ODE-351) | May 14, 2028 |
| M(M-288) | Feb 08, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 14 May, 2021
Treatment: Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (pnh) by administration of 1080 mg of pegcetacoplan twice weekly; Treatment of adult patients with paroxysmal nocturnal hemoglobinu...
Dosage: SOLUTION;SUBCUTANEOUS
EMPAVELI family patents
